6489 LOGO20THELANSIS 1

The diagnosed cases of Congenital Atransferrinemia vary worldwide considering an inherited autosomal recessive, ranging from 0.395 to 0.43 per 1,000,000 in the USA and congenital hypotransferrinemia affected approximately 0.00022 in 10,000 people in the European Union (EU). CA appears to be the most ultra-rare disease reported globally. In the EU the total number of diagnosed cases is ~55, due to a lack of disease awareness and diagnosis patients may be diagnosed or misdiagnosed.

Congenital Atransferrinemia – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Congenital-Atransferrinemia-forecast

Comprehensive insight on patient segmentation based on age, sex, Clinical Manifestations (fatigue, anorexia, irritability, tachycardia, systolic murmur, and pallor) has been provided into the epidemiology (Incidence and Prevalence) section of the Congenital Atransferrinemia and its treatment in the 8 MM countries, covering the Unit-ed States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.

CI IMAGE

In terms of pharmacologic therapies, only one asset is under development Human apo transferrin; Sanquin Plasma Products BV. Transferrins represent a class of proteins found in biological fluids of all vertebrates and invertebrates with the property of reversi-bly binding iron. At the iron-binding site, four of the six Fe3+ coordination sites are occupied by the protein ligands (2 tyrosine, 1 histidine, and 1 aspartate residue) and two by the bidentate carbonate anion. Human transferrin is a single polypeptide chain containing 679 amino acid residues with 19 disulfide bridges.

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
Hutchinson-Gilford Progeria Syndrome – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Clostridium Difficile Infection – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Leiomyosarcoma (LMS) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Clear cell sarcoma (CCS) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Immune thrombocytopenia (ITP) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

[email protected]

[email protected]

Tags: Congenital Atransferrinemia market outlook report, Congenital Atransferrinemia, Congenital Atransferrinemia competitive landscape, Congenital Atransferrinemia market forecast